These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 36920988)

  • 41. Escape hepatitis B virus mutations in recipients of antibody to hepatitis B core antigen-positive liver grafts receiving hepatitis B immunoglobulins.
    Roche B; Roque-Afonso AM; Sebagh M; Delvart V; Duclos-Vallee JC; Castaing D; Samuel D
    Liver Transpl; 2010 Jul; 16(7):885-94. PubMed ID: 20583085
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficient Prophylactic Management of HBV Reactivation by an Information Technology Encoding System: Results of a 6-year Prospective Cohort Study.
    Notsumata K; Nomura Y; Tanaka A; Nomura Y; Ueda T; Sanada T; Watanabe H; Toya D
    Intern Med; 2020; 59(20):2457-2464. PubMed ID: 33055468
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hepatitis B Virus Vaccination after Allogeneic Hematopoietic Cell Transplantation Prevents Post-Transplantation Hepatitis B Virus Reactivation.
    Hammond SP; Ho VT; Marty FM
    Transplant Cell Ther; 2022 Jul; 28(7):402.e1-402.e5. PubMed ID: 35413458
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Low risk of hepatitis B virus reactivation in membranous nephropathy patients with resolved infection undergoing rituximab-based regimens without antiviral prophylaxis.
    Song D; Guo Y; Wang Y; Tang L
    Int Immunopharmacol; 2024 Sep; 139():112731. PubMed ID: 39068756
    [TBL] [Abstract][Full Text] [Related]  

  • 45. High-titer antibody to hepatitis B surface antigen before liver transplantation can prevent de novo hepatitis B infection.
    Su WJ; Ho MC; Ni YH; Chen HL; Hu RH; Wu YM; Chang MH; Lee PH
    J Pediatr Gastroenterol Nutr; 2009 Feb; 48(2):203-8. PubMed ID: 19179883
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Incidence and risk factors for reactivation from resolved hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs.
    Watanabe T; Fukae J; Fukaya S; Sawamukai N; Isobe M; Matsuhashi M; Shimizu M; Akikawa K; Tanimura K; Atsumi T; Koike T
    Int J Rheum Dis; 2019 Apr; 22(4):574-582. PubMed ID: 30338649
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prevalence and risk factors of hepatitis B virus reactivation in patients with solid tumors with resolved HBV infection.
    Kotake T; Satake H; Okita Y; Hatachi Y; Hamada M; Omiya M; Yasui H; Hashida T; Kaihara S; Inokuma T; Tsuji A
    Asia Pac J Clin Oncol; 2019 Feb; 15(1):63-68. PubMed ID: 29984542
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Viral prophylaxis in organ transplant patients.
    Slifkin M; Doron S; Snydman DR
    Drugs; 2004; 64(24):2763-92. PubMed ID: 15563248
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Potential risk of HBV reactivation in patients with resolved HBV infection undergoing direct-acting antiviral treatment for HCV.
    Ogawa E; Furusyo N; Murata M; Toyoda K; Hayashi T; Ura K
    Liver Int; 2018 Jan; 38(1):76-83. PubMed ID: 28618152
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hepatitis B virus reactivation in kidney transplant patients with resolved hepatitis B virus infection: Risk factors and the safety and efficacy of preemptive therapy.
    Mei T; Noguchi H; Hisadome Y; Kaku K; Nishiki T; Okabe Y; Nakamura M
    Transpl Infect Dis; 2020 Apr; 22(2):e13234. PubMed ID: 31856328
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Complete hepatitis B virus prophylaxis withdrawal in hepatitis B surface antigen-positive liver transplant recipients after longterm minimal immunosuppression.
    Lenci I; Baiocchi L; Tariciotti L; Di Paolo D; Milana M; Santopaolo F; Manzia TM; Toti L; Svicher V; Tisone G; Perno CF; Angelico M
    Liver Transpl; 2016 Sep; 22(9):1205-13. PubMed ID: 27272189
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hepatitis B virus infection in heart transplant recipients in a hepatitis B endemic area.
    Ko WJ; Chou NK; Hsu RB; Chen YS; Wang SS; Chu SH; Lai MY
    J Heart Lung Transplant; 2001 Aug; 20(8):865-75. PubMed ID: 11502409
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Low Risk of Hepatitis B Virus Reactivation in HBsAg-negative/Anti-HBc-positive Carriers Receiving Rituximab for Rheumatoid Arthritis: A Retrospective Multicenter Italian Study.
    Varisco V; Viganò M; Batticciotto A; Lampertico P; Marchesoni A; Gibertini P; Pellerito R; Rovera G; Caporali R; Todoerti M; Covelli M; Notarnicola A; Atzeni F; Sarzi-Puttini P
    J Rheumatol; 2016 May; 43(5):869-74. PubMed ID: 26879359
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The impact of hepatitis B and C positive serologies on the outcomes of non-hepatic solid organ transplantation in the United States.
    Alqahtani SA; Stepanova M; Al Shabeeb R; Eberly KL; Ong J; Younossi ZM
    J Viral Hepat; 2024 Apr; 31(4):181-188. PubMed ID: 38158773
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prediction and clinical implications of HBV reactivation in lymphoma patients with resolved HBV infection: focus on anti-HBs and anti-HBc antibody titers.
    Nishida T; Matsubara T; Yakushijin T; Inada M
    Hepatol Int; 2019 Jul; 13(4):407-415. PubMed ID: 31290069
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Incidence of post-transplant hepatitis B virus reactivation with the use of kidneys from donors with resolved hepatitis B virus infection.
    Yamada R; Morikawa K; Hotta K; Iwami D; Tanabe T; Murai S; Shinohara N; Yoshida S; Hosoda S; Kubo A; Tokuchi Y; Kitagataya T; Kimura M; Yamamoto K; Nakai M; Sho T; Suda G; Natsuizaka M; Ogawa K; Sakamoto N
    J Viral Hepat; 2022 Nov; 29(11):976-985. PubMed ID: 36031873
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hepatitis B reactivation and rituximab: a new boxed warning and considerations for solid organ transplantation.
    Martin ST; Cardwell SM; Nailor MD; Gabardi S
    Am J Transplant; 2014 Apr; 14(4):788-96. PubMed ID: 24592928
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.
    Yeo W; Chan TC; Leung NW; Lam WY; Mo FK; Chu MT; Chan HL; Hui EP; Lei KI; Mok TS; Chan PK
    J Clin Oncol; 2009 Feb; 27(4):605-11. PubMed ID: 19075267
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Monitoring of Hepatitis B Virus (HBV) DNA and Risk of HBV Reactivation in B-Cell Lymphoma: A Prospective Observational Study.
    Kusumoto S; Tanaka Y; Suzuki R; Watanabe T; Nakata M; Takasaki H; Fukushima N; Fukushima T; Moriuchi Y; Itoh K; Nosaka K; Choi I; Sawa M; Okamoto R; Tsujimura H; Uchida T; Suzuki S; Okamoto M; Takahashi T; Sugiura I; Onishi Y; Kohri M; Yoshida S; Sakai R; Kojima M; Takahashi H; Tomita A; Maruyama D; Atsuta Y; Tanaka E; Suzuki T; Kinoshita T; Ogura M; Mizokami M; Ueda R
    Clin Infect Dis; 2015 Sep; 61(5):719-29. PubMed ID: 25935551
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy.
    Kusumoto S; Arcaini L; Hong X; Jin J; Kim WS; Kwong YL; Peters MG; Tanaka Y; Zelenetz AD; Kuriki H; Fingerle-Rowson G; Nielsen T; Ueda E; Piper-Lepoutre H; Sellam G; Tobinai K
    Blood; 2019 Jan; 133(2):137-146. PubMed ID: 30341058
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.